Endocrine Abstracts

Introduction: Polycystic Ovary Syndrome (PCOS) affects 5-10% of childbearing females and, up to 20% in specific ethnic populations (i.e. South Asians and Hispanics). It is linked with a higher prevalence of obesity and metabolic dysfunction, resulting in increased risk for dyslipidaemia, impaired glucose tolerance, type 2 diabetes mellitus (T2DM) and cardiovascular diseases.Methods: This is a retrospective study of patients diagnosed with PCOS (n</em...

Background: Growing evidence suggests that hypothalamic lipid sensing plays a key role in controlling food intake, fat deposition and energy balance and that its dysregulation could lead to obesity and type 2 diabetes (T2D). Recent investigations reported that sphingosine-1-phosphate (S1P) is involved in the hypothalamic control of energy homeostasis. Intra-cerebroventricular administration of S1P decreased food intake and increased energy expenditure in rodents.<p class="...

Aims: Liraglutide 3 mg once daily is an approved, prescription injectable Glucagon Like Peptide-1 receptor agonist that, when used with a low-calorie diet and increased physical activity, can reduce excess weight in patients with obesity. MiRNAs are small non-coding single stranded RNAs that regulate gene expression post-transcriptionally by inhibiting their mRNA target translation into proteins. MiRNAs can be secreted in the blood stream and affect the molecular pathways...

Introduction: Duodenal mucosal resurfacing (DMR) is a novel therapy for T2DM. It involves the hydrothermal ablation of up to 14 cm of the duodenal mucosa through a specially designed endoscopic catheter. The procedure is performed under general anaesthesia, patients are discharged the same day and it does not involve the implantation of a foreign body. Cohort studies have demonstrated that DMR induces meaningful hbA1c reductions of 0.9–1.4% by 3 months that are largely m...